-

Sierra Oncology to Present at Three September Investor Conferences

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit. He will participate in a fireside chat discussion at the 2021 Cantor Virtual Global Healthcare Conference.

Presentation Details:

Conference:    HC Wainwright 23rd Annual Global Investment Conference
Date:   Monday, September 13, 2021
Time:   On demand viewing beginning at 7:00 am ET
   
Conference:   Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Date:   Tuesday, September 21, 2021
Time:   Presentation beginning at 2:05 pm ET
   
Conference:   2021 Cantor Virtual Global Healthcare Conference
Date:   Tuesday, September 28, 2021
Time:   Fireside chat beginning at 4:00 pm ET

All three presentations will be webcast and available at the times noted above on the Investors section of Sierra’s corporate website in the Events & Webcast tab.

About Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. We harness our deep scientific expertise to identify compounds that target the root cause of disease. Our team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Together we are transforming promise into patient impact.

For more information, visit www.SierraOncology.com.

Contacts

Investor Contact
DeDe Sheel
415.732.9828
dsheel@sierraoncology.com

Media Contact
Lauren Musto
615.351.7777
lmusto@sierraoncology.com

Sierra Oncology

NASDAQ:SRRA

Release Versions

Contacts

Investor Contact
DeDe Sheel
415.732.9828
dsheel@sierraoncology.com

Media Contact
Lauren Musto
615.351.7777
lmusto@sierraoncology.com

Social Media Profiles
More News From Sierra Oncology

Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. “Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team...

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2022, in Chicago and online. An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and a...

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation. Addi...
Back to Newsroom